Big spike in sales growth for IMC’s Travelan® product
Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC; NASDQ: IMRN) has today informed the market of the impressive half year sales results for its over-the-counter gastrointestinal and digestive health supplement Travelan®.
The product saw strong sales growth throughout the first half of the 2018 financial year, both in the US and Australia, with the company reporting A$335,000 in sales in the US market — a 250 per cent increase on the same period last year — and A$579,000 in sales in the Australian market, a 27 per cent increase on the same period last year.
Of course, it should be noted that Immuron is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
IMC is a small-cap biotech focused on the treatment of several gut mediated diseases in the realm of oral immunotherapies. Its popular Travelan® product is already available for purchase, while the company’s other immunotherapies — one designed to treat C. Difficile infection and another to treat NASH disease — are still in developmental stages.
In commenting on today’s news, Immuron Marketing Manager David Montgomery said: “Key factors that have positively impacted the ongoing sales momentum include the continued focus on improving the execution of our trade marketing strategy in both the US and Australian markets.
“We are anticipating that the same sales trajectory will continue for Travelan® for the remainder of the 2018 financial year to target our aim of achieving in excess of A$2 million in annual sales for the first time.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.